Document Detail

ACS chemical neuroscience molecule spotlight on viibryd (Vilazodone).
MedLine Citation:
PMID:  22860155     Owner:  NLM     Status:  MEDLINE    
On January 21, 2011, the U.S. Food and Drug Administration approved Viibryd, a new selective serotonin reuptake inhibitor (SSRI), to treat major depressive disorder in adults developed by Clinical Data, Inc.
Corey R Hopkins
Related Documents :
23480875 - Comparable lumefantrine oral bioavailability when co-administered with oil-fortified ma...
24987525 - Emphasising personal investment effects weight loss and hedonic thoughts about food aft...
21424985 - Intake of high-intensity sweeteners alters the ability of sweet taste to signal caloric...
21204935 - Sphaerodes mycoparasitica biotrophic mycoparasite of 3-acetyldeoxynivalenol- and 15-ace...
9430615 - Reduced food intake in zinc deficient rats is normalized by megestrol acetate but not b...
20811865 - Perfluorinated substances in human food and other sources of human exposure.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  ACS chemical neuroscience     Volume:  2     ISSN:  1948-7193     ISO Abbreviation:  ACS Chem Neurosci     Publication Date:  2011 Oct 
Date Detail:
Created Date:  2012-08-03     Completed Date:  2013-04-11     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  101525337     Medline TA:  ACS Chem Neurosci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  554     Citation Subset:  IM    
Department of Pharmacology and Chemistry and Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, United States.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antidepressive Agents / adverse effects,  therapeutic use*
Benzofurans / adverse effects,  therapeutic use*
Depressive Disorder, Major / drug therapy,  psychology
Indoles / adverse effects,  therapeutic use*
Middle Aged
Multicenter Studies as Topic
Piperazines / adverse effects,  therapeutic use*
Psychiatric Status Rating Scales
Randomized Controlled Trials as Topic
Serotonin Uptake Inhibitors / adverse effects,  therapeutic use*
Young Adult
Reg. No./Substance:
0/Antidepressive Agents; 0/Benzofurans; 0/Indoles; 0/Piperazines; 0/Serotonin Uptake Inhibitors; S239O2OOV3/vilazodone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A simple strain typing assay for Trypanosoma cruzi: discrimination of major evolutionary lineages fr...
Next Document:  Adenosine A(2A) Receptor Antagonists and Parkinson's Disease.